Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

Results 1 - 20 of 40 : 1 2 Next »

Recs

3
Member Avatar zzlangerhans (99.77) Submitted: 2/3/2014 6:05:14 PM : Outperform Start Price: $1.76 LXRX Score: -25.37

Lexicon stock is declining but I think it's mostly a tidal effects related to a market correction and weakness in speculative sectors like s,mall cap biopharma. I've made my issues with Lexicon's valuation clear and the street as responded over and over again by taking the market cap back over a billion. I haven't seen anything to tell me this time will be any different.

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:27:22 PM : Underperform Start Price: $2.46 LXRX Score: +56.52

Short. Biopharma. No real revenues to speak of, just lots of selling their own stock.

Recs

0
Member Avatar FelipeCersosimo (< 20) Submitted: 3/7/2013 11:57:31 AM : Outperform Start Price: $2.05 LXRX Score: -53.03

When deal-activity begins to slow it is a signal that prices in the market may begin to move lower. M&A activity is common at a market bottom because lower stock prices are attractive to potential acquirers as they look to consolidate competitors and grab more market share.

Recs

0
Member Avatar adunlap13 (< 20) Submitted: 2/25/2013 1:46:37 PM : Outperform Start Price: $1.99 LXRX Score: -54.06

Big diabetes market for there main drug LX4211. It's the only drug that inhibits SLGT1 and SLGT2 which can treat both type 1 diabetes and type 2. No one has taken notice of this stock yet. They are also going to be partnering in the next few months with a large biopharma company to get LX4211 rolling.

Recs

1
Member Avatar NHWeston (< 20) Submitted: 11/30/2012 1:57:36 PM : Outperform Start Price: $1.70 LXRX Score: -49.17

A small company that gets very little attention, working in apparently random areas like bowel issues and rheumatiod arthritis. Diabetes, however, is a research zone where they've suddenly picked up and, with a current price slip, insiders and board members are accumulating shares hand over fist. Speculative, but promising.

Recs

0
Member Avatar KimLanners (< 20) Submitted: 10/5/2011 3:27:53 PM : Outperform Start Price: $0.92 LXRX Score: -5.56

biopha

Recs

0
Member Avatar kannankeril (79.02) Submitted: 9/21/2011 10:13:09 PM : Outperform Start Price: $1.08 LXRX Score: -32.59

Like all medical research companies, this one carries risk but they have ownership of good idea and the price is lower than the strike price that was granted to the last investor that made a big investment in the company.

Recs

1
Member Avatar sandybdr (73.90) Submitted: 8/16/2011 4:15:58 PM : Outperform Start Price: $1.30 LXRX Score: -46.52

Biopharma company that works on mouse genetics , localizes potential drug targets , and then attempts to make drugs specific for those targets. Completely speculative play. If LX4211 succeeds (phase IIb trial currently enroling; results available in 2012) then it would get partnered with big pharma. That being said, a similar drug from Astra Zeneca just got shot down by the FDA.
I would peg their chance of success at 1 in 3.
They do have 3 more in the pipeline , 2 for irritable bowel syndrone and one for rheumatoid arthritis.

Chance of a further dilution before the end of the year ~ 100%
chance of being partnered or bought out by big pharma for a successful drug ~ 25%
If the pipeline falls through, chance of going to zero by late 2012~ 100% !!!!
Worth a speculative flier, the underlying technology and methodology is completely sound.... Though not necessarily enough to ensure success!

Recs

0
Member Avatar eatenbybears (< 20) Submitted: 6/17/2011 3:36:02 PM : Outperform Start Price: $1.54 LXRX Score: -56.13

Kick'n butt in court

Recs

1
Member Avatar Brosan (< 20) Submitted: 1/28/2011 11:31:06 AM : Underperform Start Price: $1.79 LXRX Score: +68.36

With more less than 80c per share available in cash, LXRX will have a very hard time to keep their heads above water. The me-too compound, LX4211, seems to be stuck in the ground due to the lack of interest in the pharma community. Even it finds a partner, this will take ages (+3 years at least) to be on the market. There are enough alternatives on the diabetes markets and more developed phase 3s anywhere that LX4211 would seem like a DOA (Dead On Arrival). I think the best way to move forward with LXRX is get rid of the current CEO (A. Sands) and replace the entire Board of Directors. Then, try to sell the sole effective compound LX1032 to a specialty cancer or gut specialty drugmaker and sell the ground/building/labs to a fellow Texan drugmaker. Call it a day! It's over.

Recs

0
Member Avatar omarsharif123 (33.18) Submitted: 6/23/2010 5:09:39 PM : Outperform Start Price: $1.30 LXRX Score: -63.03

It has several durgs in the pipeline and one or two have good change to get to the market. This is a potential grand slam stock.

Recs

0
Member Avatar iddqkfyou (< 20) Submitted: 4/5/2010 6:53:26 PM : Outperform Start Price: $1.59 LXRX Score: -70.68

Just a random bet with high upside and lower downside.

Recs

0
Member Avatar Contralogic (< 20) Submitted: 1/31/2010 5:52:36 PM : Outperform Start Price: $1.80 LXRX Score: -97.88

2014-2015 play.

Recs

2
Member Avatar rumblinac (86.60) Submitted: 12/20/2009 3:18:38 PM : Outperform Start Price: $1.93 LXRX Score: -99.32

Hans( porte) likes it ....I did the technicals for him...the correct buy point was 1.31...this is a break-out point - hopefully!

Recs

0
Member Avatar topsecret10 (< 20) Submitted: 10/13/2009 6:05:07 PM : Outperform Start Price: $1.52 LXRX Score: -81.16

Very limited downside risk at this level. Invus Is showing their support In taking a larger equity Interest In recent stock offering[ at $1.50 per share] " We work with our owner-managers to come up with the right capital structure to realize our joint vision and make sure we are fully aligned. We do not load up companies with a heavy debt burden to boost our returns and hope for the best. In fact, we often make investments that are 100% equity.
We have invested in companies across a wide range of industries including consumer products and services, food, specialty retail, software, biotech, medical devices and products and services to professionals. Although most of our investments have been in the US and Europe, we have invested in companies across the world leveraging our flexible structure and the international background of our team." Lots to like about their drug pipeline,load up at this price level....... TS

Recs

0
Member Avatar bluesinjid (< 20) Submitted: 10/12/2009 12:46:23 PM : Outperform Start Price: $1.52 LXRX Score: -82.54

NIce cheap price:)

Recs

0
Member Avatar jfsinvest (< 20) Submitted: 10/10/2009 1:32:22 PM : Outperform Start Price: $1.26 LXRX Score: -60.96

Mouse type bio-tech

Recs

0
Member Avatar DavidBear (< 20) Submitted: 10/8/2009 9:35:06 AM : Outperform Start Price: $1.79 LXRX Score: -100.02

Company has a number of irons in the fire. Recent diabetes phase I result looks promising (although short in length), the concept behind it is sound.

Recs

1
Member Avatar topsecret09 (36.84) Submitted: 9/25/2009 8:15:29 PM : Outperform Start Price: $2.04 LXRX Score: -113.72

I have done a lot of research on this one,and I like it a lot. Not only do they have a strong drug pipeline,they have the financial backing of Invus, which seeks out companies to Invest In and provide capital for that are deemed In their opinion to have considerable Intrinsic value as the company grows,and matures."We know what it takes to transform an industry: strategic insight, patient capital and great execution. We support owner-managers on all three of these dimensions.." Some of the officers of INVUS sit on the board of directors at LEXICON,Including the President and CEO. I consider this stock a long term accumulate especially under $2.50 per share. I would be willing to buy this one all the way up to $6.00 In the coming months. I hope that It stays depressed for awhile so I can pick up shares on the cheap. I do not believe that this stock will remain under $4.00 for very long..... TS

Recs

0
Member Avatar tylerfu (43.81) Submitted: 7/11/2008 2:24:28 AM : Outperform Start Price: $1.78 LXRX Score: -79.22

speculative cap

Results 1 - 20 of 40 : 1 2 Next »

Featured Broker Partners


Advertisement